中国现代药物应用
中國現代藥物應用
중국현대약물응용
CHINESE JOURNAL OF MODERN DRUG APPLICATION
2014年
24期
8-9,10
,共3页
重型肝炎%肠黏膜屏障%枯草杆菌二联活菌肠溶胶囊%乳果糖%内毒素%血氨
重型肝炎%腸黏膜屏障%枯草桿菌二聯活菌腸溶膠囊%乳果糖%內毒素%血氨
중형간염%장점막병장%고초간균이련활균장용효낭%유과당%내독소%혈안
Severe hepatitis%Intestinal mucosal barrier%Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules%Lactulose%Endotoxin%Blood ammonia
目的:探讨枯草杆菌二联活菌肠溶胶囊(美常安)联合乳果糖对重型肝炎患者肠黏膜屏障功能的影响。方法43例重型肝炎患者随机分为对照组(19例)和治疗组(24例),两组均给予美常安口服;治疗组加用乳果糖口服液。所有患者均于治疗前后测定内毒素(ETX)含量、血氨及胆红素等其他指标,另选12例健康体检者作为正常对照组。结果治疗组及对照组治疗后血清总胆红素等指标均较治疗前有明显下降,不适症状亦有明显改善;两组血清治疗前ETX水平、血氨水平均高于正常对照组,差异有统计学意义(P<0.05);两组患者治疗后血清ETX水平、血氨水平较治疗前水平下降,治疗组下降较对照组下降更明显,差异有统计学意义(P<0.05)。结论重型肝炎患者血清ETX水平、血氨水平高于正常人,肠黏膜屏障功能下降;口服补充肠道益生菌可改善肠黏膜屏障功能,乳果糖联合美常安可保护肠黏膜屏障功能,显著降低重型肝炎患者血氨水平。
目的:探討枯草桿菌二聯活菌腸溶膠囊(美常安)聯閤乳果糖對重型肝炎患者腸黏膜屏障功能的影響。方法43例重型肝炎患者隨機分為對照組(19例)和治療組(24例),兩組均給予美常安口服;治療組加用乳果糖口服液。所有患者均于治療前後測定內毒素(ETX)含量、血氨及膽紅素等其他指標,另選12例健康體檢者作為正常對照組。結果治療組及對照組治療後血清總膽紅素等指標均較治療前有明顯下降,不適癥狀亦有明顯改善;兩組血清治療前ETX水平、血氨水平均高于正常對照組,差異有統計學意義(P<0.05);兩組患者治療後血清ETX水平、血氨水平較治療前水平下降,治療組下降較對照組下降更明顯,差異有統計學意義(P<0.05)。結論重型肝炎患者血清ETX水平、血氨水平高于正常人,腸黏膜屏障功能下降;口服補充腸道益生菌可改善腸黏膜屏障功能,乳果糖聯閤美常安可保護腸黏膜屏障功能,顯著降低重型肝炎患者血氨水平。
목적:탐토고초간균이련활균장용효낭(미상안)연합유과당대중형간염환자장점막병장공능적영향。방법43례중형간염환자수궤분위대조조(19례)화치료조(24례),량조균급여미상안구복;치료조가용유과당구복액。소유환자균우치료전후측정내독소(ETX)함량、혈안급담홍소등기타지표,령선12례건강체검자작위정상대조조。결과치료조급대조조치료후혈청총담홍소등지표균교치료전유명현하강,불괄증상역유명현개선;량조혈청치료전ETX수평、혈안수평균고우정상대조조,차이유통계학의의(P<0.05);량조환자치료후혈청ETX수평、혈안수평교치료전수평하강,치료조하강교대조조하강경명현,차이유통계학의의(P<0.05)。결론중형간염환자혈청ETX수평、혈안수평고우정상인,장점막병장공능하강;구복보충장도익생균가개선장점막병장공능,유과당연합미상안가보호장점막병장공능,현저강저중형간염환자혈안수평。
Objective To investigate the influence of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules (Medilac-s) combined with lactulose on intestinal mucosal barrier function of severe hepatitis patients. Methods A total of 43 severe hepatitis patients were randomly divided into control group with 19 cases and treatment group with 24 cases, and the two groups received oral administration of Medilac-s. The treatment group received additional lactulose oral liquid for treatment. The levels of endotoxin (ETX), blood ammonia, and bilirubin of the patients were detected before and after treatment. Another 12 healthy people were enrolled as the normal control group. Results The levels of total serum bilirubin and other indexes were decreased in the treatment and control groups, compared with those before treatment, and the discomfort symptom was improved. Both groups had higher levels of ETX and blood ammonia than the normal control group before treatment, and the difference had statistical significance (P<0.05). After treatment, the levels of ETX and blood ammonia were much lower than those before treatment, and the decrease in the treatment group was much more obvious than that in the control group, and the difference had statistical significance (P<0.05). Conclusion The levels of ETX, blood ammonia, and bilirubin of severe hepatitis patients are higher than those of health people, and their intestinal mucosal barrier function declines. The supplement of intestinal probiotics through oral administration can improve intestinal mucosal barrier function, which can be protected by the combination of Medilac-s and lactulose. This treatment can also significantly reduce the level of blood ammonia in severe hepatitis patients.